Haige Shen

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

You Lü, Jianxin Xue, Tao Deng et al. · Nature Medicine · 2020 · 537 citations

Life Sciences, Biotechnology, Oncology +14

Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema

Ursula Schmidt‐Erfurth, Gabriele E. Lang, Frank G. Holz et al. · Ophthalmology · 2014 · 314 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +17

KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.

Vanesa Gregorc, María González‐Cao, Stefania Salvagni et al. · Journal of Clinical Oncology · 2024 · 26 citations

Medicine, Oncology, Pharmacology +17

A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).

Hai‐Qiang Mai, Ye Guo, Muh-Hwa Yang et al. · Journal of Clinical Oncology · 2023 · 20 citations

Medicine, Oncology, Pharmacology +17

A phase I randomized, <scp>double‐blinded</scp>, <scp>placebo‐controlled</scp> study assessing the safety and pharmacokinetics of <scp>RIPK1</scp> inhibitor <scp>GFH312</scp> in healthy subjects

Jason D. Lickliter, Shuang Wang, Wenxin Zhang et al. · Clinical and Translational Science · 2023 · 20 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15